Skip to main content
. 2009 Aug;175(2):489–499. doi: 10.2353/ajpath.2009.080727

Figure 6.

Figure 6

Parthenolide, a NF-κB inhibitor, inhibits AR expression, PSA secretion and cell proliferation in prostate cancer cells. A: Inhibition on AR transcription in LNCaP cells treated with parthenolide. AR mRNA levels measured using real-time RT-PCR. LNCaP cells (50% to 60% confluent) were treated with parthenolide (0, 2, 5, and 10 μg/ml) for 6 hours in RPMI 1640 supplemented with 10% FBS. The data represent at least two independent experiments. B: Parthenolide significantly inhibited AR and p65 expression in LNCaP cells in a dose-dependent manner. LNCaP cells (50% to 60% confluent) were treated with parthenolide (0, 2, 5, and 10 μg/ml) for 6 hours in RPMI 1640 supplemented with 10% FBS before cell harvest and Western blot analysis. C: PSA secretion was significantly inhibited in LNCaP cells treated with parthenolide using enzyme-linked immunosorbent assay. D: Proliferation assay demonstrating dose-dependent inhibition of prostate cancer cell proliferation with the NF-κB inhibitor, parthenolide. The readings are normalized to controls. Data represent at least two independent experiments.